Population pharmacokinetic research for biologic agents in IBD, such as anti-TNF agents (infliximab) and anti-integrin agents (vedolizumab), has recognized high body weight as a risk factor correlated with the augmented drug clearance [131,132], suggesting that augmented levels of adipose-produced TNF confiscate anti-TNF agents. Here, TNF is linked to inflammatory bowel disease.